Relationship of Plasma HIV‐1 RNA Dynamics to Baseline Factors and Virological Responses to Highly Active Antiretroviral Therapy in Adolescents (Aged 12–22 Years) Infected through High‐Risk Behavior
Author(s) -
Hulin Wu,
Janet L. Lathey,
Ping Ruan,
Steven D. Douglas,
Stephen A. Spector,
Jane C. Lindsey,
Michael D. Hughes,
Bret J. Rudy,
Patricia M. Flynn
Publication year - 2004
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/381500
Subject(s) - zidovudine , efavirenz , viral load , lamivudine , regimen , virology , nelfinavir , lentivirus , medicine , immunology , viral disease , biology , virus , antiretroviral therapy , hepatitis b virus
We characterized the viral dynamics of human immunodeficiency virus (HIV) type 1-infected adolescents receiving highly active antiretroviral therapy regimens (lamivudine [3TC]/zidovudine [ZDV]/efavirenz [EFV], 3TC/ZDV/nelfinavir [NFV], or other regimens) and studied the relationship of viral dynamics with baseline factors and virological responses. Viral decay rates for 115 evaluable subjects were estimated from a viral dynamic model. Viral dynamics in HIV-1-infected individuals aged 12-22 years were similar to those of HIV-1-infected adults and infants. Individuals who received 3TC/ZDV/EFV had a more rapid phase 1 viral decay rate than those who received 3TC/ZDV/NFV or other regimens. Phase 1 viral decay rates were positively correlated with baseline RNA levels and week 1 virus load reductions. Our findings indicate that the 3TC/ZDV/EFV regimen may be more potent than 3TC/ZDV/NFV or other regimens and that early viral dynamics or week 1 virus load reduction measurements may be useful in evaluating the potency of antiretroviral regimens.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom